George Dunbar
Venture Partner @ Arboretum Ventures
Detroit, United States
George Dunbar is a funding round investor at Arboretum Ventures in Detroit focused on Content and Health Care. George Dunbar joined Arboretum Ventures in 2010 as a Venture Partner. George utilizes his extensive healthcare operating experience as the former CEO of a number of venture-backed healthcare companies to evaluate new investment opportunities in diagnostics, life science tools, and medical devices. George currently serves as the Executive Chairmanof the Board of Directors at CerviLenz and serves on the boards of directors for KFx Medical and IntelliCyt Corporation.Prior to joining Arboretum, George was the President, CEO, and Chairman of Aastrom Biosciences [NASDAQ: ASTM], a clinical development stage healthcare company based in Ann Arbor, Michigan. Prior to Aastrom, George worked with several national venture capital firms, serving as the CEO of early-stage life sciences companies, including Quantum Dot (acquired by Invitrogen) and Epic Therapeutics (acquired by Baxter Healthcare).
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries George Dunbar invests in
Stages George Dunbar invests in
Countries George Dunbar invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Content 1 (50%)
- Health Care 1 (50%)
- Life Science 1 (50%)
- Biotechnology 1 (50%)
Stage
- Funding Round 1 (50%)
- Venture - Series Unknown 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, reagent kits, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells andbeads. IntelliCyt’s products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences.Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet needs in phenotypic small molecule drug discovery, antibody discovery, in vitro toxicology as well as other high profile research areas. By combining the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, IntelliCyt’s HTFC Screening System enables suspension cell assays at speeds up to 40x faster than traditional flow cytometry. IntelliCyt has integrated HTFC with application-specific reagent kits and informatics software to address the growing market for high throughput cell based assays to provide earlier, more physiologically relevant results at lower cost. | $7.4M / Venture - Series Unknown / Oct 22, 2015 | ||
| IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, reagent kits, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells andbeads. IntelliCyt’s products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences.Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet needs in phenotypic small molecule drug discovery, antibody discovery, in vitro toxicology as well as other high profile research areas. By combining the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, IntelliCyt’s HTFC Screening System enables suspension cell assays at speeds up to 40x faster than traditional flow cytometry. IntelliCyt has integrated HTFC with application-specific reagent kits and informatics software to address the growing market for high throughput cell based assays to provide earlier, more physiologically relevant results at lower cost. | $8M / May 06, 2013 |
Co-Investors
New Mexico Community Capital
1 deal together
Prolog Ventures
1 deal together
Verge Fund
1 deal together
About Arboretum Ventures
Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and lifescience tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million.Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.
Arboretum Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Paul McCreadie
Managing Partner and Chief Operating Officer
|
|||
Robert Cesaro
Associate
|
|||
Tim Petersen
Founder and Managing Partner
|
|||
Amanda Goldstein
Executive Assistant
|
|||
|
George Dunbar
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does George Dunbar invest in?
George Dunbar invests primarily in Content, Health Care and Life Science startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact George Dunbar?
Public channels for George Dunbar include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did George Dunbar last invest?
The most recent investment recorded for George Dunbar closed in Oct 2015. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
